Cargando…

P873: IXAZOMIB VERSUS LENALIDOMIDE OR IXAZOMIB AND LENALIDOMIDE COMBINATION AS MAINTENANCE REGIMEN FOR TRANSPLANT-INELIGIBLE MULTIPLE MYELOMA: UPDATE OF A MULTI-CENTER PROSPECTIVE STUDY IN CHINA

Detalles Bibliográficos
Autores principales:	Zhuang, Zhe, Tian, Ying, Shi, Lei, Yu, Hong, Liu, Qinhua, Zou, Dongmei, Tian, Weiwei, Feng, Ru, Dong, Fei, MA, Yanping, Liu, Shuangjiao, Jing, Hongmei, Liu, Hui, MA, Liangming, Sun, Wanling, Fu, Rong, Bao, LI, Wu, Yin, Chen, Wenming, Zhuang, Junling
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Lippincott Williams & Wilkins 2023
Materias:	Posters
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10430926/ http://dx.doi.org/10.1097/01.HS9.0000970396.32254.68

Ejemplares similares

P978: IXAZOMIB VERSUS LENALIDOMIDE OR IXAZOMIB AND LENALIDOMIDE COMBINATION AS MAINTENANCE REGIMEN FOR PATIENTS WITH MULTIPLE MYELOMA: INTERIM ANALYSIS OF A MULTI-CENTER PROSPECTIVE STUDY IN CHINA
por: Zhuang, Z., et al.
Publicado: (2022)

Oral ixazomib, lenalidomide, and dexamethasone for transplant-ineligible patients with newly diagnosed multiple myeloma
por: Facon, Thierry, et al.
Publicado: (2021)

P959: MAINTENANCE THERAPY FOLLOWED AUTOLOGOUS STEM CELL TRANSPLANTATION BY IXAZOMIB AND/OR LENALIDOMIDE IN PATIENTS WITH NEWLY DIAGNOSED MULTIPLE MYELOMA: A MULTICENTERED REAL WORLD STUDY IN CHINA
por: Lu, Minqiu, et al.
Publicado: (2023)

Ixazomib combined with lenalidomide and dexamethasone chemotherapy for newly diagnosed multiple myeloma in China—Compared with bortezomib/lenalidomide/dexamethasone
por: Huo, Zhongjun, et al.
Publicado: (2022)

Ixazomib, lenalidomide, and dexamethasone in patients with newly diagnosed multiple myeloma: long-term follow-up including ixazomib maintenance
por: Kumar, Shaji K., et al.
Publicado: (2019)

Safety and Efficacy of Combination Maintenance Therapy with Ixazomib and Lenalidomide in Patients with Posttransplant Myeloma
por: Patel, Krina K., et al.
Publicado: (2022)

Twice‐weekly ixazomib in combination with lenalidomide‐dexamethasone in patients with newly diagnosed multiple myeloma
por: Richardson, Paul G., et al.
Publicado: (2018)

Management of adverse events associated with ixazomib plus lenalidomide/dexamethasone in relapsed/refractory multiple myeloma
por: Kumar, Shaji, et al.
Publicado: (2017)

Survival benefit of ixazomib, lenalidomide and dexamethasone (IRD) over lenalidomide and dexamethasone (Rd) in relapsed and refractory multiple myeloma patients in routine clinical practice
por: Minarik, Jiri, et al.
Publicado: (2021)

Real World Efficacy and Safety Results of Ixazomib Lenalidomide and Dexamethasone Combination in Relapsed/Refractory Multiple Myeloma: Data Collected from the Hungarian Ixazomib Named Patient Program
por: Varga, Gergely, et al.
Publicado: (2019)

Real-world effectiveness of ixazomib combined with lenalidomide and dexamethasone in relapsed/refractory multiple myeloma: the REMIX study
por: Macro, M., et al.
Publicado: (2023)

Lenalidomide or bortezomib as maintenance treatment remedy the inferior impact of high-risk cytogenetic abnormalities in non-transplant patients with newly diagnosed multiple myeloma: a real-world multi-centered study in China
por: Zhuang, Zhe, et al.
Publicado: (2023)

c‐MYC expression and maturity phenotypes are associated with outcome benefit from addition of ixazomib to lenalidomide‐dexamethasone in myeloma
por: Di Bacco, Alessandra, et al.
Publicado: (2020)

Ixazomib-based induction regimens plus ixazomib maintenance in transplant-ineligible, newly diagnosed multiple myeloma: the phase II, multi-arm, randomized UNITO-EMN10 trial
por: Mina, Roberto, et al.
Publicado: (2021)

Combined Therapy with Ixazomib, Lenalidomide, and Dexamethasone for Polyneuropathy, Organomegaly, Endocrinopathy, Monoclonal Gammopathy, and Skin Changes Syndrome
por: Suichi, Tomoki, et al.
Publicado: (2022)

Impact of prior therapy on the efficacy and safety of oral ixazomib-lenalidomide-dexamethasone vs. placebo-lenalidomide-dexamethasone in patients with relapsed/refractory multiple myeloma in TOURMALINE-MM1
por: Mateos, María-Victoria, et al.
Publicado: (2017)

Pharmacokinetics and safety of ixazomib plus lenalidomide–dexamethasone in Asian patients with relapsed/refractory myeloma: a phase 1 study
por: Gupta, Neeraj, et al.
Publicado: (2015)

Clinical benefit of ixazomib plus lenalidomide‐dexamethasone in myeloma patients with non‐canonical NF‐κB pathway activation
por: Dash, Ajeeta B., et al.
Publicado: (2020)

Efficacy and Safety of Ixazomib Plus Lenalidomide and Dexamethasone Following Injectable PI-Based Therapy in Relapsed/Refractory Multiple Myeloma
por: Abe, Yu, et al.
Publicado: (2023)

Correction to: Efficacy and safety of ixazomib plus lenalidomide and dexamethasone following injectable pi‑based therapy in relapsed/refractory multiple myeloma
por: Abe, Yu, et al.
Publicado: (2023)

Comparison between ixazomib+cyclophosphamide+dexamethasone regimen and ixazomib+dexamethasone regimen for elderly and frail patients having newly diagnosed multiple myeloma
por: Li, Shutan, et al.
Publicado: (2022)

Mechanistic Insights in Hemophagocytic Lymphohistiocytosis: Subsequent Acute Hepatic Failure in a Multiple Myeloma Patient Following Therapy with Ixazomib-Lenalidomide-Dexamethasone
por: Constantinescu, Catalin, et al.
Publicado: (2022)

Ixazomib, Lenalidomide and Dexamethasone in Relapsed and Refractory Multiple Myeloma in Routine Clinical Practice: Extended Follow-Up Analysis and the Results of Subsequent Therapy
por: Minarik, Jiri, et al.
Publicado: (2022)

P929: CIRCULATING TUMOR DNA ASSESSMENT IMPROVES PROGNOSTIC PREDICTION IN RELAPSED/REFRACTORY MULTIPLE MYELOMA RECEIVING IXAZOMIB, LENALIDOMIDE, AND DEXAMETHASONE
por: Kogure, Yasunori, et al.
Publicado: (2023)

Randomized, double-blind, placebo-controlled phase III study of ixazomib plus lenalidomide-dexamethasone in patients with relapsed/refractory multiple myeloma: China Continuation study
por: Hou, Jian, et al.
Publicado: (2017)

Daratumumab‐lenalidomide‐dexamethasone vs standard‐of‐care regimens: Efficacy in transplant‐ineligible untreated myeloma
por: Durie, Brian G. M., et al.
Publicado: (2020)

P901: DARATUMUMAB, IXAZOMIB AND DEXAMETHASONE IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA PRE-TREATED WITH A LENALIDOMIDE-BASED REGIMEN: FINAL OUTCOMES OF THE PHASE 2 DARIA STUDY
por: Terpos, Evangelos, et al.
Publicado: (2023)

A phase 2, open-label, multicenter study of ixazomib plus lenalidomide and dexamethasone in adult Japanese patients with relapsed and/or refractory multiple myeloma
por: Iida, Shinsuke, et al.
Publicado: (2021)

Impact of ixazomib‐lenalidomide‐dexamethasone therapy on overall survival in multiple myeloma patients: Analysis of the emerging‐markets subgroup of the TOURMALINE‐MM1 trial
por: Spencer, Andrew, et al.
Publicado: (2022)

Ixazomib-Associated Skin Exfoliation
por: Zhang, Yali, et al.
Publicado: (2022)

Oral ixazomib-dexamethasone vs oral pomalidomide-dexamethasone for lenalidomide-refractory, proteasome inhibitor-exposed multiple myeloma: a randomized Phase 2 trial
por: Dimopoulos, Meletios A., et al.
Publicado: (2022)

PB2019: EFFICACY AND SAFETY OF IXAZOMIB PLUS LENALIDOMIDE AND DEXAMETHASONE FOLLOWING INJECTABLE PROTEASOME INHIBITOR-BASED THERAPY IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA
por: Sasaki, M., et al.
Publicado: (2022)

A phase I/II dose-escalation study investigating all-oral ixazomib-melphalan-prednisone induction followed by single-agent ixazomib maintenance in transplant-ineligible newly diagnosed multiple myeloma
por: San-Miguel, Jesús F., et al.
Publicado: (2018)

Ixazomib–Thalidomide–Dexamethasone for induction therapy followed by Ixazomib maintenance treatment in patients with relapsed/refractory multiple myeloma
por: Ludwig, Heinz, et al.
Publicado: (2019)

Sweet Syndrome Associated with Ixazomib
por: Yavaşoğlu, İrfan, et al.
Publicado: (2021)

Spotlight on ixazomib: potential in the treatment of multiple myeloma
por: Muz, Barbara, et al.
Publicado: (2016)

T‐cell pseudolymphoma secondary to ixazomib for multiple myeloma
por: Haq, M., et al.
Publicado: (2021)

PB2038: LENALIDOMIDE OR BORTEZOMIB AS MAINTENANCE TREATMENT OVERCOMES INFERIOR IMPACT OF HIGH-RISK CYTOGENETIC ABNORMALITIES IN TRANSPLANT-INELIGIBLE PATIENTS WITH NEWLY DIAGNOSED MULTIPLE MYELOMA IN CHINA
por: Zhuang, Z., et al.
Publicado: (2022)

P925: IMPACT OF PRIOR TREATMENT EXPOSURE ON THE EFFECTIVENESS OF IXAZOMIB-LENALIDOMIDE-DEXAMETHASONE IN RELAPSED/REFRACTORY MULTIPLE MYELOMA PATIENTS TREATED IN ROUTINE CLINICAL PRACTICE (THE INSURE STUDY)
por: Lee, H. C., et al.
Publicado: (2022)

P49 A REAL-WORLD RETROSPECTIVE-PROSPECTIVE ANALYSIS OF EFFICACY AND SAFETY OF COMBINED IXAZOMIB, LENALIDOMIDE AND DEXAMETHASONE IN RELAPSED/REFRACTORY MULTIPLE MYELOMA: THE NORTHERN ITALY EXPERIENCE
por: Furlan, A., et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_1thfu4otnv0dbjcrcbjvlb98o9